Usefulness of Cardiac Index and Peak Exercise Oxygen Consumption for Determining Priority for Cardiac Transplantation

Decisions regarding cardiac transplantation listing are difficult in patients with heart failure who have relatively discordant peak exercise oxygen consumption (VO2) and cardiac index (CI) values. One hundred five patients with heart failure who underwent cardiopulmonary exercise testing and right-sided cardiac catheterization for transplantation evaluation were studied. Patients were divided into 4 groups on the basis of peak VO2 and CI: group 1, VO2 >= 12 ml/min/kg, CI >= 1.8 L/min/m(2) (n = 30); group 2, VO2 >= 12 ml/min/kg, CI <1.8, L/min/m(2) (n = 27); group 3, VO2 <12 ml/min/kg, CI >= 1.8 L/min/m(2) (n = 25); and group 4, VO2 <12 ml/min/kg, CI <1.8 L/min/m(2) (n = 23). Groups were compared for event-free (death or ventricular assist device) survival. The overall CI was 1.9 +/- 0.4 L/min/m(2) and peak VO2 was 12.4 +/- 2.8 ml/min/kg; values in the 4 groups were as follows: group 1, peak VO2 14.7 +/- 2.1 ml/min/kg, CI 2.2 +/- 0.3 L/min/m(2); group 2, peak VO2 14.2 +/- 1.3 ml/min/kg, CI 1.5 +/- 0.2 L/min/m(2); group 3, peak VO2 10.2 +/- 1.3 ml/min/kg, CI 2.1 +/- 0.3 L/min/m(2); and group 4, peak VO2 9.7 +/- 2.0 ml/min/kg, CI 1.6 +/- 0.2 L/min/m(2). After a median follow-up period of 3.7 years, 28 patients (26.0%) had events. Event-free survival was 96%, 95%, 96%, and 79% for 6 months (p = 0.04); 88%, 81%, 90%, and 73% for 12 months (p = 0.09); 88%, 73%, 85%, and 65% for 18 months (p = 0.11); and 83%, 73%, 79%, and 53% for 24 months (p = 0.06) for groups 1 to 4, respectively. Median survival was 5.1, 3.0, 3.9, and 2.6 years, respectively, in groups 1 to 4 (p = 0.052). In conclusion, almost half the patients had relatively discordant peak VO2 and CI measurements. Patients with lower peak VO2 values but relatively preserved CI values had survival comparable to post-transplantation survival, whereas those with low CI but preserved VO2 had a lower survival rate. These results suggest that the former group may be safely monitored on medical therapy, whereas the latter may benefit from early listing. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;105:1353-1355)